National Venture Conference

Opportunities Abound

Posted by ecreese on April 23, 2008 at 11:40am EDT

Attendees awoke to the news this morning about GlaxoSmithKline’s announcement that it will pay millions — $720 million to be exact — for Sirtris Pharmaceuticals. This is the stuff biotech CEOs dream about. And it was the buzz at many breakfast tables at this morning’s workshop, “Antibiotics: Bad Bugs – Few Drugs.”

BIO National Venture Conference Off to a Strong Start

Posted by ecreese on April 22, 2008 at 3:21pm EDT

While the economy may not be as robust as it has in recent years, there certainly was no sign of that at today’s Opening Luncheon. Jim Greenwood, our President & CEO welcomed attendees to the inaugural BIO National Venture Conference and cited these impressive stats:

Welcome to Boston!

Posted by ecreese on April 22, 2008 at 1:36pm EDT

The marathon may be over, but that doesn't mean there isn't plenty more activity going on here in Boston.    We're here in Cambridge, one of biotechnology's "hot-spots" for the inaugural BIO National Venture Conference meeting up with some of the newest early stage and seed stage companies seeking venture funding.  Stay tuned for more as the program gets underway...

Syndicate content